Another phase III study demonstrated that first-line erlotinib treatment of patients with EGFR mutation-positive NSCLC provides a statistically significant improvement in PFS in comparison to chemotherapy treatment with gemcitabine/cisplatin (11.0 months versus 5.5 months) [94] or docetaxel/cisplatin (9.7 months versus 5.2 months) [92]. Here, EGFR is linked to non-small cell lung carcinoma.